Influenza A virus A/Kansas/14/2017 (H3N2) recombinant hemagglutinin antigen

DB15518ApprovedWithdrawnVaccines

Influenza A virus A/Kansas/14/2017 (H3N2) recombinant hemagglutinin antigen is a recombinant hemagglutinin used in seasonal influenza vaccines. A seasonally-specific component of the influenza vaccine.

First approval: United States, 2019

Resolves to

Compound

UNIII282A48KKK

What you can answer from here — as of April 02, 2025

1ContraindicationEach with its own population and attribute set

2Marketed productsAcross 2 countries and 2 labellers

1+ReferenceStructured and connected to the statements they support

Which companies are running trials of Influenza A virus A/Kansas/14/2017 (H3N2) recombinant hemagglutinin antigen, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account